Apollomics, Inc.
NCM: APLMLive Quote
📈 ZcoreAI Score
Our AI model analyzes Apollomics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get APLM Z-Score →About Apollomics, Inc.
Healthcare
Biotechnology
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
📊 Fundamental Analysis
Apollomics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 380.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -380.1%, which indicates that capital utilization is currently under pressure.
At a current price of $13.60, APLM currently sits at the 26th percentile of its 52-week range (Range: $3.66 - $42.12).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$29.20M
Trailing P/E
--
Forward P/E
-20.92
Beta (5Y)
1.83
52W High
$42.12
52W Low
$3.66
Avg Volume
11K
Day High
Day Low